טוען...
Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...
שמור ב:
| הוצא לאור ב: | ACS Omega |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Chemical Society
2020
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758955/ https://ncbi.nlm.nih.gov/pubmed/33376898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c04942 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|